Itacitinib + Everolimus for Hodgkin Lymphoma

Recruiting in Palo Alto (17 mi)

Overseen by Jakub Svoboda, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 1 & 2

Waitlist Available

Sponsor: University of Pennsylvania

No Placebo Group

Trial Summary

What is the purpose of this trial?

This is an open-label, single-group, Phase I/II study of itacitinib in combination with everolimus in subjects with relapsed or refractory classical Hodgkin lymphoma (cHL).

Research Team

Jakub Svoboda, MD

Principal Investigator

University of Pennsylvania

Eligibility Criteria

Adults with relapsed classical Hodgkin lymphoma who've had at least two prior treatments and aren't eligible for high-dose therapy can join. They must have measurable disease, not be candidates for certain other therapies, and be free from other cancers for 2+ years. Good organ function is required, as well as agreement to use contraception.

Inclusion Criteria

I can obtain everolimus through my insurance or by paying myself.

I can take care of myself and am up and about more than half of my waking hours.

I am not pregnant and agree to use birth control.

Exclusion Criteria

Pregnant or breast-feeding females

Presence of conditions or laboratory abnormalities that place the subject at unacceptable risk or confound data interpretation

I am not using other cancer treatments while in this study.

Treatment Details

Interventions

• Everolimus (mTOR Inhibitor)
• Itacitinib (Janus Kinase (JAK) Inhibitor)

Trial Overview This study tests Itacitinib combined with Everolimus in patients with Hodgkin lymphoma that has come back or hasn't responded to treatment. It's an early-phase trial where everyone gets the same drugs to see how safe they are and if they work.

Participant Groups

Group I: Itacitinib and everolimus Experimental Treatment 2 Interventions

Who Is Running the Clinical Trial?

University of Pennsylvania

Lead Sponsor

Trials

2,118

Recruited

45,270,000+

Dr. Joan Lau

University of Pennsylvania

Chief Executive Officer since 2020

PhD in Neuroscience from the University of Cincinnati College of Medicine, MBA from the Wharton School of Business, BS in Bioengineering from the University of Pennsylvania

Dr. Robert Iannone

University of Pennsylvania

Chief Medical Officer since 2019

MD from Yale University, MSCE from the University of Pennsylvania